What is Jade Biosciences, Inc.'s (JBIO) StockRank?

MoatMap's StockRank for Jade Biosciences, Inc. (JBIO) is 24/100, with a Sell signal. This is a composite score combining Quality (37), Value (28), and Momentum (45) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Jade Biosciences, Inc. have an economic moat?

Jade Biosciences, Inc. (JBIO) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Jade Biosciences, Inc. a buy, hold, or sell?

MoatMap's current signal for Jade Biosciences, Inc. (JBIO) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Jade Biosciences, Inc. in?

Jade Biosciences, Inc. (JBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

JBIO

SellSinker

Jade Biosciences, Inc. · Healthcare · United States · $1.3B · Avg Vol: $15M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-38.3%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for various medical conditions. Its therapeutic approach aims to address unmet medical needs, providing potential for significant market impact if successful. The company is a research-driven biotech enterprise seeking to bring innovative therapies to market.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	2027E	Fwd CAGR
Revenue	—	0	—	—	—	—
EPS	—	-3.19	-1.07	-2.93	-2.66	—
Shares	32.2M	49.3M	63.6M	—	—	—
Debt	107.6M	0.7M	1.4M	—	—	—
Equity	-46.8M	332.5M	—	—	—	—
Op CF	—	-94.7M	-123.5M	—	—	—
Inv CF	—	-247.0M	—	—	—	—
Fin CF	—	360.8M	—	—	—	—

Loading 1Y...

PRICE (1Y)-4.3%

SMA 50SMA 200

$19.14

RSI (14)

30.6

52W High

$28.00

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-34.1%22.0

ROE

-38.3%22.3

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

—N/A

Piotroski

339.0

Int. Cover

—N/A

D/E Ratio

0.00x90.6

Current Ratio

14.93x92.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.9x25.0

P/FCF

—N/A

P/B

2.9x47.9

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

68%46.8

RS 6M

24%80.2

SMA 50/200

1.17x85.7

EPS Rev 4W

-16.8%5.6

EPS Rev 12W

—N/A

EPS Improve

-149%3.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.3B

P/E (Forward)

-7.5x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JBIO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
JBIO	Jade Biosciences, Inc.(you)	$1.3B	24	Sell
MNKD	MannKind Corporation	$1.3B	25	Sell
CGEM	Cullinan Therapeutics, Inc.	$1.3B	26	Sell
ORIC	ORIC Pharmaceuticals, Inc.	$1.4B	22	Sell
VOR	Vor Biopharma Inc.	$1.3B	20	Sell
KURA	Kura Oncology, Inc.	$1.1B	23	Sell
AVBP	ArriVent BioPharma, Inc.	$1.5B	22	Sell
AVTX	Avalo Therapeutics, Inc.	$1.1B	26	Sell
REPL	Replimune Group, Inc.	$1.5B	19	Strong Sell
JANX	Janux Therapeutics, Inc.	$1.1B	28	Sell

Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%

Jade Biosciences, Inc. (JBIO): Stock Score Summary

Jade Biosciences, Inc. (JBIO) has a MoatMap StockRank of 24/100 based on Quality (37/100), Value (28/100), and Momentum (45/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$19.14
Market Cap	$1.3B
P/E (Forward)	-7.47
Price/Book	2.87
Return on Equity	-38.3%
Return on Invested Capital	-34.1%
Debt/Equity	0.00x
Gross Margin	0.0%
Operating Margin	0.0%

Jade Biosciences, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Jade Biosciences, Inc.’s (JBIO) StockRank?: MoatMap’s StockRank for Jade Biosciences, Inc. (JBIO) is 24/100, with a Sell signal. It is a composite of Quality (37), Value (28), and Momentum (45) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Jade Biosciences, Inc. have an economic moat?: Jade Biosciences, Inc. (JBIO) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jade Biosciences, Inc. a buy, hold, or sell?: MoatMap’s current signal for Jade Biosciences, Inc. (JBIO) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Jade Biosciences, Inc. in?: Jade Biosciences, Inc. (JBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).